Genzyme, Isis Begin New Drug Trials
Ryan McBride1/12/09
Genzyme (NASDAQ:GENZ) and Isis Pharmaceuticals (NASDAQ:ISIS) say the biotech firms have begun two new late-stage clinical trials and have started screening patients for a third new study of cholesterol-lowering drug mipomersen, aiming to ratchet up the amount of data on patients treated with the drug over the next 18 months. Luke caught up with Cambridge, MA-based Genzyme last year to discuss the large biotech firm’s foray into the multibillion-dollar market for drugs that lower cholesterol with mipomersen-developer Isis, headquartered in San Diego.
